阿立哌唑治疗老年精神分裂症的疗效和安全性观察

Observations on efficacy and safety of aripiprazole used for treating patients with senile schizophrenia

目的：观察阿立哌唑治疗老年精神分裂症的临床疗效和安全性。方法：70例老年精神分裂症患者随机分为以下2组：阿立哌唑组[男性17例，女性18例，年龄（66.2±2．4）岁]和氟哌啶醇组[男性18例，女性17例，年龄（65．4±2、4）岁]。阿立哌唑组和氟哌啶组的起始剂量分别为5-10mg／d和2mg／d，之后视病情分别调整为（12.8±3.3）mg／d和（7.3±3．6）mg／d，共治疗8周。采用阳性症状与阴性症状量表（PANSS）评定临床疗效，用不良反应症状量表（TESS）评定不良反应。结果：阿立哌唑组与氟哌啶醇组的有效率分别为88．6％和85．7％，2组比较差异无统计学意义（P〉0．05）。阿立哌唑组不良反应少而轻微。结论：阿立哌唑为治疗老年精神分裂症的有效安全药物。

Objective： To observe the efficacy and safety of aripiprazole used for treating patients with senile schizophrenia. Methods： Seventy patients with senile schizophrenia were randomly divided into following two groups： aripiprazole group [17 males, 18 females, age（66.2±2.4） years] and haloperidol group [18 males, 17 females, age（65.4±2.4） years].The initia/dosages for the aripiprazole and haloperidol groups were 5-10 mg/d and 2 mg/d respectively, and then adjusted to （12.8±3.3） mg/d and （7.3±3.6） mg/d respectively according to the condition of disease. The duration of therapy was 8 weeks. PANSS was used to assess the clinical efficacy, and TESS was used to assess adverse reactions. Results： The effective rate in the aripiprazole and haloperidol groups was 88.6% and 85.7% respectively. There were no stastistically deferences between the two groups （P〉0.05）. The adverse reactions of aripiprazole were mild and less. Conclusion： Aripiprazole is an effective and safe drug used for treating patients with senile schizophrenia.